Copiktra (Duvelisib) for Leukemia | MyLeukemiaTeam

Connect with others who understand.

sign up Log in
About MyLeukemiaTeam
Powered By

Copiktra is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL) in adults. Copiktra is indicated in cases where leukemia has relapsed or failed at least two previous therapies. Copiktra is also referred to by its drug name, duvelisib.

Copiktra is used as targeted therapy for leukemia. Copiktra is a member of a class of drugs called kinase inhibitors. Copiktra is believed to work by inhibiting cancer cell growth.

How do I take it?
Prescribing information states that Copiktra is taken orally twice a day.

Copiktra comes in the form of a capsule.

Side effects
The FDA-approved label for Copiktra lists common side effects including fever, fatigue, cough, upper respiratory infection, pain in the muscles or bones, nausea, diarrhea, intestinal inflammation, rash, and low blood cell counts.

Rare but serious side effects listed for Copiktra include liver damage, life-threatening infections, skin reactions, gastrointestinal inflammation, and lung inflammation.

For more details about this treatment, visit:

Copiktra — Verastem Oncology

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in